

Citations and Reference Literature: PABA

Citations

1. Hughes CG. Oral PABA and vitiligo. *J Am Acad Dermatol* 1983;9:770.
2. Kantor GR, Ratz JL. Liver toxicity from potassium para-aminobenzoate. *J Am Acad Dermatol* 1985;13:671-672.
3. Zarafonitis CJD, Grekin RH, Curtis AC et al. Further studies on the treatment of lupus erythematosus with sodium para-aminobenzoate. *J Invest Dermatol* 1948;11:359.
4. Worobec S, LaChine A. Dangers of orally administered para-aminobenzoic acid. *JAMA* 1984;251:2348.
5. Degowin RL, Eppes RB, Carson PE et al. The effects of diaphenylsulfone (DDS) against chloroquine-resistant *Plasmodium falciparum*. *Bull World Health Organ* 1966;34:671-681.
6. Irshaid YM, al-Hadidi HF, Abuirjeie MA et al. Acetylation of dapsone by human whole blood. *Int J Clin Pharmacol Ther Toxicol* 1993;31:18-22.
7. McConkey GA, Ittarat I, Meshnick SR, McCutchan TF. Auxotrophs of *Plasmodium falciparum* dependent on p-aminobenzoic acid for growth. *Proc Natl Acad Sci USA* 1994;91:4244-4248.
8. Voeller D, Kovacs J, Andrawis V et al. Interaction of *Pneumocystis carinii* dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone). *J Infect Dis* 1994;169:456-459.
9. Ehler C, Strunz H, Visser K et al. Inhibition of the conjugation of PABA with glycine in vitro by sulfamoyl benzoic acids, sulfonamides, and penicillins and its relation to tubular secretion. *J Pharm Sci* 1998;87:785.
10. Vinnicombe HG, Derrick JP. Dihydropteroate synthase from *Streptococcus pneumoniae*: characterization of substrate binding order and sulfonamide inhibition. *Biochem Biophys Res Commun* 1999;258:752-757.
11. Castelli LA, Nguyen NP, Macreadie IG. Sulfa drug screening in yeast: fifteen sulfa drugs compete with p-aminobenzoate in *Saccharomyces cerevisiae*. *FEMS Microbiol Lett* 2001;199:181-184.
12. Brooks P. In vitro and in vivo radiosensitization by p-aminobenzoic acid (PABA): Abstract 1005. International Conference on Molecular Targets and Cancer Therapeutics. New York; 2003.
13. Antineoplastics, antimetabolites, methotrexate. In: Threlkeld DS, ed. *Facts and Comparisons Drug Information*. St Louis: Facts and Comparisons; 1990:653-654.
14. Hendel J, Nyfors A. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. *Eur J Clin Pharmacol* 1984;26:121-124.
15. Morgan SL, Baggott JE, Vaughn WH et al. 5 mg or 50 mg/week dose of folic acid supplementation does not alter the efficacy of methotrexate treated rheumatoid arthritis patients (abstract). *Arthritis Rheum* 1993;36:S79.
16. Morgan S, Alarcon GS, Krumdieck CL. Folic acid supplementation during methotrexate therapy: it makes sense. *J Rheumatol* 1993;20:929-930.
17. Shiroky JB, Neville C, Esdaile JM et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 1993;36:795-803.
18. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. *J Am Acad Dermatol* 1993;28:466-469.
19. Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. *Ann Intern Med* 1994;121:833-841.
20. Ortiz Z, Shea B, Suarez-Almazor ME et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. *J Rheumatol* 1998;25:36-43.
21. Bressolle F, Kinowski JM, Morel J et al. Folic acid alters methotrexate availability in patients with rheumatoid arthritis. *J Rheumatol* 2000;27:2110-2114.

Reference Literature

- [No authors listed.] Drug evaluations subscription. Vol. 2. Section 13. Chicago: American Association; 1993.
- [No authors listed.] Physicians' desk reference. Montvale, NJ: Medical Economics Co, Inc; 2003.
- Baca AM, Sirawaraporn R, Turley S, et al. Crystal structure of *Mycobacterium tuberculosis* 7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfa-drug action. *J Mol Biol* 2000;302(5):1193-1212.
- Birdsall B, Burgen AS, Roberts GC. Effects of coenzyme analogues on the binding of p-aminobenzoyl-L-glutamate and 2,4-diaminopyrimidine to *Lactobacillus casei* dihydrofolate reductase. *Biochemistry* 1980;19(16):3732-3737.
- Cannon WR, Garrison BJ, Benkovic SJ. Consideration of the pH-dependent inhibition of dihydrofolate reductase by methotrexate. *J Mol Biol* 1997;271(4):656-668.
- Carson CC. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective? *Tech Urol* 1997;3:135-139.

Citations and Reference Literature: PABA

- Castelli LA, Nguyen NP, Macreadie IG. Sulfa drug screening in yeast: fifteen sulfa drugs compete with p-aminobenzoate in *Saccharomyces cerevisiae*. *FEMS Microbiol Lett* 2001;199(2):181-184.
- Clegg DO, Reading JC, Mayes MD. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. *J Rheumatol* 1994;21:105-110.
- Ehlert C, Strunz H, Visser K, et al. Inhibition of the conjugation of PABA with glycine in vitro by sulfamoyl benzoic acids, sulfonamides, and penicillins and its relation to tubular secretion. *J Pharm Sci* 1998;87(1):101-108.
- Fan H, Brunham RC, McClarty G. Acquisition and synthesis of folates by obligate intracellular bacteria of the genus *Chlamydia*. *J Clin Invest* 1992;90(5):1803-1811.
- Gaby AR. The story of PABA. *Nutr Healing* 1997; 3-4,11. (Review)
- Grace WJ, Kennedy RJ, Formato A. Therapy of scleroderma and dermatomyositis. *N Y State J Med* 1963;63:140-144.
- Hasche-Klunder R. Treatment of Peyronie's disease with para-aminobenzoic potassium (Potoba). *Urologe [A]* 1978;17:224-247.
- Holt GA. Food and drug interactions. Chicago: Precept Press; 1998:170.
- Hughes CG. Oral PABA and vitiligo. *J Am Acad Dermatol* 1983;9:770. (Letter)
- Hyde JE, Sims PF. Sulfa-drug resistance in *Plasmodium falciparum*. *Trends Parasitol* 2001;17(6):265-256.
- Irshaid YM, al-Hadidi HF, Abuirjeie MA, et al. Acetylation of dapsone by human whole blood. *Int J Clin Pharmacol Ther Toxicol* 1993;31(1):18-22.
- Kantor GR, Ratz JL. Liver toxicity from potassium para-aminobenzoate. *J Am Acad Dermatol* 1985;13:671-672. (Letter)
- Ludwig G. Evaluation of conservative therapeutic approaches to Peyronie's disease (fibrotic induration of the penis). *Urol Int* 1991;47:236-239.
- McConkey GA, Ittarat I, Meshnick SR, et al. Auxotrophs of *Plasmodium falciparum* dependent on p-aminobenzoic acid for growth. *Proc Natl Acad Sci U S A* 1994;91(10):4244-4248.
- Rosowsky A, Wright JE, Vaidya CM, et al. The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxyteroyl)-N(delta)-hemiphthaloyl-L- ornithine. *Pharmacol Ther* 2000;85(3):191-205.
- Sieve BF. Further investigations in the treatment of vitiligo. *Virginia Med Monthly* 1945:6-17.
- Sieve BF. The clinical effects of a new B-complex factor, para-aminobenzoic acid, on pigmentation and fertility. *South Med Surg* 1942;104:135-139.
- Then RL. Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole. *Rev Infect Dis* 1982;4(2): 261-269. (Review)
- Voeller D, Kovacs J, Andrawis V, et al. Interaction of *Pneumocystis carinii* dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone). *J Infect Dis* 1994;169(2):456-459.
- Voice RA, Manis M, Weber WW. Inhibition of human red blood cell N-acetyltransferase. *Drug Metab Dispos* 1993;21(1):181-183.
- Wiesel LL, Barritt AS, Stumpe WM. The synergistic action of para-aminobenzoic acid and cortisone in the treatment of rheumatoid arthritis. *Am J Med Sci* 1951;222:243-248.
- Willis I, Kligman AM. Aminobenzoic acid and its esters: the quest for more effective sunscreens. *Arch Dermatol* 1970;102:405-417.
- Worobec S, LaChine A. Dangers of orally administered para-aminobenzoic acid. *JAMA* 1984;251:2348.
- Zarafonetis CJD, Curtis AC, Shaw JM. Treatment of pemphigus with potassium para-aminobenzoate. *Am J Med Sci* 1956;231:30-50.
- Zarafonetis CJ, Dabich L, Devol EB, et al. Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacity. *Respiration* 1989;56:22-33.
- Zarafonetis CJD, Dabich L, Negri D, et al. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. *J Clin Epidemiol* 1988;41:193-205.
- Zarafonetis CJ, Dabich L, Skovronski JJ. Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapy. *Clin Exp Rheumatol* 1988;6:261-268.
- Zarafonetis CJD, Grekin RH, Curtis AC, et al. Further studies on the treatment of lupus erythematosus with sodium para-aminobenzoate. *J Invest Dermatol* 1948;11:359.
- Zarafonetis CJD. Darkening of gray hair during para-amino-benzoic acid therapy. *J Invest Dermatol* 1950;15:399-401.
- Zarafonetis CJD. The treatment of scleroderma: results of potassium para-aminobenzoate therapy in 104 cases. In: Mills LC, Moyer JH, eds. *Inflammation and diseases of connective tissue*. Philadelphia: Saunders; 1961:688-696.
- Zarafonetis CJD. Treatment of Peyronie's disease with potassium para-aminobenzoate. *J Urol* 1959;81:770-772.